4D Molecular Therapeutics Stock Soars 26.25% on Clinical Trial Progress

On April 2, 2025, 4D Molecular Therapeutics' stock price surged by 26.25% in pre-market trading, marking a significant rise in investor interest and confidence in the company's prospects.

4D Molecular Therapeutics' stock price recently hit a 52-week low at $3.46, reflecting a period of market volatility and investor caution. This low point may have been influenced by various factors, including broader market trends and company-specific developments.

Recent updates from the company indicate that the enrollment pace in the RESET clinical development program has accelerated to approximately one patient per week since the ACR Convergence presentation in November. This increase in enrollment suggests a positive trajectory for the company's clinical trials, which could potentially drive future stock price movements.